Patients with active acromegaly (growth hormone overproduction from a pituitary tumor) are treated with a new somatostatin analogue pasireotide. If you have questions or wish to participate in this study, please contact our Study Coordinator, Betsy Staudinger RN, at (713) 873-8772 or email For more information see An Acromegaly, Open-Label, Multi-Center, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy (ACCESS).